The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other.
The first four subprotocols include the following:
Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
≥ 18 years of age
ECOG PS is 0 to 1
Adequate organ function as outlined by the study
Received prior standard therapy appropriate for tumor type and stage
Primary central nervous system (CNS) tumors
Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
Major surgery < 28 days of first dose
Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids
Revolution Medicines, Inc.
Lead sponsor